1Kanj SS,Welty-Wolf K,Madden J,et al.Fungal infections in lung and heart-lungtransplant recipients.report of 9 cases and review of the literature.Medicine,1996,75:142-56.
2Edmond MB,Wallace SE,McClish DK,et al,Nosocomial blood-stream infectious in United States hospitals:a three-year analysis[J].Clin Infect Dis,1999,29(2)∶239-244.
3Kauffman CA,Carrer PL.Antifungal agents in the 1990s.Current status and future developments[J].Drugs,1997,53(4)∶539-549.
6Higgins JP,Greens.Cochrane Handbook for Systematic Reviews of Intervention (Version 5.1.0).Available at:http://www.cochrane-handbook.org.
7Budde K,Curtis J,Knoll G,et al.Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients:results of a 1-year study.Am J Transplant,2004,4 (2):237-243.
8Ciancio G,Gaynor JJ,Zarak A,et al.Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance:four-year analysis.Transplantation,2011,91(11):1198-1205.
9Ciancio G,Burke GW,Gaynor JJ,et al.Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin:One year follow-up.Transplantation,2008,86 (1):67-74.
10Ortega F,Sanchez-Fructuoso A,Cruzado JM,et al.Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents:mycophenolate mofetil and enteric-coated mycophenolate sodium.Transplantation,2011,92 (4):426-432.
